Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 11;59(11):e430-e433.
doi: 10.1515/cclm-2021-0326. Print 2021 Oct 26.

Belantamab mafodotin detection by MASS-FIX and immunofixation

Patrick W Mellors  1 , Mindy C Kohlhagen  2 , Surendra Dasari  2 , Maria A V Willrich  2 , Morie A Gertz  3 , Shaji K Kumar  3 , Martha Q Lacy  3 , David L Murray  2 , Angela Dispenzieri  3   2
Affiliations

Belantamab mafodotin detection by MASS-FIX and immunofixation

Patrick W Mellors et al. Clin Chem Lab Med. .
No abstract available

Keywords: belantamab mafodotin; immunofixation; mass spectrometry; multiple myeloma.

PubMed Disclaimer

References

    1. van de Donk, NW, Otten, HG, El Haddad, O, Axel, A, Sasser, AK, Croockewit, S, et al.. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med 2016;54:1105–9. https://doi.org/10.1515/cclm-2015-0888.
    1. Milani, P, Murray, DL, Barnidge, DR, Kohlhagen, MC, Mills, JR, Merlini, G, et al.. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol 2017;92:772–9. https://doi.org/10.1002/ajh.24772.
    1. Mills, JR, Kohlhagen, MC, Willrich, MAV, Kourelis, T, Dispenzieri, A, Murray, DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 2018;132:670–2. https://doi.org/10.1182/blood-2018-05-848986.
    1. Tai, YT, Mayes, PA, Acharya, C, Zhong, MY, Cea, M, Cagnetta, A, et al.. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123:3128–38. https://doi.org/10.1182/blood-2013-10-535088.
    1. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [news release]. U.S. Food and Drug Administration. Silver Spring, MD: US FDA; 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accel... [Accessed 26 Jan 2020].

Publication types

Substances

LinkOut - more resources